Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Endovascular Ablation Of The Right Greater Splanchnic Nerve In Subjects Having Heart Failure With Reduced Ejection Fraction: Randomized Controlled Feasibility Trial

NCT07403058 is registered in ClinicalTrials.gov with Axon Therapies, Inc. as lead sponsor.

NCT NCT07403058
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07403058 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Endovascular Ablation Of The Right Greater Splanchnic Nerve In Subjects Having Heart Failure With Reduced Ejection Fraction: Randomized Controlled Feasibility Trial
Lead sponsor
Axon Therapies, Inc.
Phase
Not applicable
Overall status
Not yet recruiting
Start date
March 1, 2026
Completion date
September 1, 2028
Enrollment
50 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

heart failure with reduced ejection fraction (hfref)